Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Headquartered in La Jolla, CA Fiscal year ends December NASDAQ: CALC calcimedica.com
CalciMedica is a pre-revenue, clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors for serious inflammatory, immunologic and cardiopulmonary diseases.
Its pipeline contains two distinct compounds:
- Zegocractin, formulated for intravenous use as Auxora, has been evaluated in more than 350 patients. It is being developed for pulmonary hypertension (a planned Phase 1b proof-of-concept trial with data anticipated mid-2027) and acute pancreatitis (an FDA-aligned Phase 2b design using LDH-based enrichment and severe respiratory failure as the primary endpoint, with initiation subject to additional financing).
- CM5480 is an oral CRAC channel inhibitor designed for chronic dosing in PH, including PAH and PH associated with heart failure with preserved ejection fraction. An IND submission is anticipated mid-2027.
Auxora was previously studied in the CARPO (acute pancreatitis), CARDEA (COVID-19 pneumonia) and KOURAGE (acute kidney injury) trials; KOURAGE will not be restarted.
The company trades on the Nasdaq Capital Market under CALC and completed a 1-for-5 reverse stock split in August 2026. Updated
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
CalciMedica is a pre-revenue, clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors for serious inflammatory, immunologic and cardiopulmonary diseases.
The Wall Street consensus 12-month price target for CALC is $42.00.